Clinical pharmacology of Miami

Miami, Florida 33172

5 studies enrolling now · 77 studies all time

What they study most

Acute Pain, Alzheimer Disease, Bioequivalence, Bunion, COVID-19, Cardiac Failure, Cirrhosis, Liver, Diabetes Mellitus, Type 2, Drug Interactions, End Stage Renal Disease, Healthy, Healthy Participants

Studies at this site

• Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib — Recruiting now
• Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D — Recruiting now
• A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes — Recruiting now
• A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function — Recruiting now
• Evaluation of Non-Invasive Tests for Metabolic Liver Disease — Recruiting now
• A Study of LY3971297 in Healthy Participants — Running, not enrolling
• Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid — Running, not enrolling
• A Study of TLC590 for Postsurgical Pain Following Bunionectomy — Running, not enrolling
• A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function — Running, not enrolling
• A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes — Running, not enrolling
• A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment. — Completed
• A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy — Completed
• A Study of LY3502970 in Participants With Impaired and Normal Liver Function — Completed
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight — Completed
• A Study of LY3537031 in Overweight, Obese, and Healthy Participants — Running, not enrolling
• A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants — Completed
• A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants — Completed
• A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants — Completed
• A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function — Completed
• A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants — Completed
• Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function — Completed
• A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants — Completed
• A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883. — Completed
• A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants — Completed
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants — Completed
• A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function — Completed
• A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain — Completed
• A Study of TAK-279 in Adults With or Without Kidney Problems — Completed
• A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function — Completed
• A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib — Completed
• A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function — Completed
• Fruquintinib Renal Impairment Study — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function — Completed
• A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants — Completed
• A Study of LY3819469 in Healthy Participants — Completed
• Fruquintinib Hepatic Impairment Study — Completed
• KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment — Completed
• A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function — Completed
• Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects — Completed
• Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function — Completed
• A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt) — Completed
• The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects — Completed
• Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers — Completed
• Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function — Completed
• Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects — Completed
• Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt) — Withdrawn before enrolling
• Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects — Completed
• A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM — Completed